Parthenolide, a natural compound from the feverfew plant, stimulates GLP-1 secretion from human intestinal cells by activating the bitter taste receptor TAS2R4 and triggering calcium-dependent hormone release.
Dose-dependent GLP-1 secretionParthenolide stimulated GLP-1 release from human intestinal cells in a dose-dependent manner through direct activation of the bitter taste receptor TAS2R4
What the researchers found
Parthenolide (PTL), a natural compound found in feverfew, was identified as a high-affinity agonist of the bitter taste receptor TAS2R4 that stimulates GLP-1 secretion from human intestinal cells in a dose-dependent manner. Direct binding to TAS2R4 was confirmed by cellular thermal shift assays, and molecular docking revealed strong interactions including hydrogen bonding with specific receptor residues.
The mechanism involves PTL activating TAS2R4, which upregulates phospholipase C β2 (PLCβ2) to produce IP3, triggering calcium release inside the cell. This calcium increase drives GLP-1 vesicle fusion and secretion. Calcium also activates the TRPM5 channel, further amplifying the signal. This establishes parthenolide as a natural compound that can boost the body's own GLP-1 production through a bitter taste receptor pathway.
Why it matters
GLP-1 drugs like semaglutide are revolutionizing diabetes and obesity treatment, but they require injections and are expensive. An alternative approach is to stimulate the body's own GLP-1 production using natural compounds. Bitter taste receptors in the gut — the same type that detect bitterness on the tongue — can trigger GLP-1 release when activated. Finding natural agonists for these receptors could lead to functional foods or supplements that boost endogenous GLP-1, potentially offering a dietary complement to pharmaceutical approaches for blood sugar management.
The numbers in context
Parthenolide: high-affinity TAS2R4 agonist · dose-dependent GLP-1 secretion · hydrogen bonding with ASN-65 · hydrophobic contacts with PHE-62 and PHE-88 · calcium-dependent vesicle fusion · PLCβ2/IP3/TRPM5 signaling pathway
How the study worked
Researchers screened the BitterDB and BitterX databases to identify natural bitter compounds with GLP-1-inducing potential. Parthenolide was selected as a TAS2R4 agonist candidate. Direct binding was confirmed by cellular thermal shift assay (CETSA). Molecular docking revealed specific binding interactions. GLP-1 secretion was measured in human Caco-2 enteroendocrine cells after parthenolide treatment. Intracellular signaling was characterized through TAS2R4 expression analysis, PLCβ2 pathway activation, calcium imaging, and TRPM5 channel involvement.
Who was studied
Human Caco-2 enteroendocrine cell line
What this study cannot tell us
This is entirely an in vitro study using Caco-2 cells (a human colon cancer cell line used to model intestinal cells), not primary human gut cells or in vivo testing. Caco-2 cells may not perfectly replicate the GLP-1 secretion dynamics of native L-cells in the human intestine. No animal or human data exists for parthenolide's GLP-1-stimulating effects. Parthenolide's bioavailability, safety profile at GLP-1-stimulating doses, and potential interactions with other medications are not addressed.
How to read the evidence
This study is graded as preliminary because all experiments were conducted in Caco-2 cells (a cell culture model). No animal or human testing was performed, and the gap between in vitro GLP-1 stimulation and in vivo metabolic effects is substantial.
When this study was published
Published in 2026, this is a brand-new study at the cutting edge of bitter taste receptor pharmacology and natural GLP-1 secretagogue research.
The bigger picture
The discovery that gut bitter taste receptors can trigger GLP-1 release has opened a new field of 'bitter compound pharmacology.' If natural bitter agonists like parthenolide can meaningfully boost endogenous GLP-1, they could serve as dietary adjuncts to existing diabetes therapies — potentially at a fraction of the cost of injectable GLP-1 drugs. This study also highlights the intriguing biology of extra-oral taste receptors, which are reshaping how we understand the gut-hormone axis and its role in metabolic disease.
Questions still open
- Can parthenolide raise GLP-1 levels enough in living humans to have a meaningful effect on blood sugar or appetite?
- Would a feverfew-based supplement or functional food product deliver sufficient parthenolide to the gut to activate TAS2R4?
- Are there other natural bitter compounds that activate different TAS2R subtypes and could have additive GLP-1-stimulating effects?
Common questions
Can bitter foods help your body produce more GLP-1?
What is parthenolide and is it safe?
Read the original research
Parthenolide promotes glucagon-like peptide-1 secreting in human Caco-2 cells via regulation of bitter taste receptor-induced of calcium signaling.
Molecular and cellular biochemistry, 481(2), 775-789
Citation
Li, Shanshan; Chen, Ye; Song, Zhaosu; Ou, Penghui; Duan, Yujing; Liu, Qinglei; Wang, Wei. (2026). Parthenolide promotes glucagon-like peptide-1 secreting in human Caco-2 cells via regulation of bitter taste receptor-induced of calcium signaling.. Molecular and cellular biochemistry, 481(2), 775-789. https://doi.org/10.1007/s11010-025-05425-6